Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1983 Mar;78(3):489–505. doi: 10.1111/j.1476-5381.1983.tb08809.x

Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors.

J C Doxey, A G Roach, C F Smith
PMCID: PMC2044721  PMID: 6132640

Abstract

1 The selectivity and specificity of RX 781094 [2-(2-(1,4 benzodioxanyl))2-imidazoline HCl] for alpha-adrenoceptors have been examined in peripheral tissues. 2 In isolated tissue experiments RX 781094 was a competitive antagonist at prejunctional alpha 2-adrenoceptors situated on the sympathetic nerve terminals of the rat (pA2 = 8.56) and mouse (pA2 = 7.93) vas deferens and on the parasympathetic nerve terminals of the guinea-pig ileum (pA2 = 8.55). 3 Although RX 781094 was also a competitive antagonist at the postjunctional alpha 1-adrenoceptors of the rat anococcygeus muscle (pA2 = 6.10) its affinity for these receptors was markedly less than that displayed for prejunctional sites. From pA2 values obtained in the rat vas deferens and anococcygeus muscle the calculated alpha 2/alpha 1-adrenoceptor selectivity ratio for RX 781094 was 288. 4 The rank order of alpha 2/alpha 1-adrenoceptor selectivities for the antagonists studied was RX 781094 greater than RS 21361 greater than yohimbine greater than piperoxan greater than phentolamine greater than WB 4101 greater than prazosin. 5 RX 781094 had extremely low affinity for beta-adrenoceptors, histamine receptors, cholinoceptors, 5-hydroxytryptamine and opiate receptors in vitro. 6 In pithed rats, intravenous administration of RX 781094 antagonized the prejunctional alpha 2-adrenoceptor agonist effects of clonidine and guanabenz on electrically-induced contractions of the vas deferens and anococcygeus muscle respectively. 7 In the vas deferens the rank order of alpha 2-adrenoceptor antagonist potencies was RX 781094 greater than phentolamine greater than piperoxan greater than yohimbine greater than RS 21361 greater than WB 4101. Only RX 781094, yohimbine and RS 21361 were active against guanabenz in the anococcygeus muscle. 8 In the pithed rat, RX 781094 preferentially antagonized the pressor responses evoked by postjunctional alpha 2-adrenoceptor activation by UK 14,304 although higher doses also inhibited the effects of phenylephrine and cirazoline at postjunctional alpha 1-adrenoceptors. 9 RX 781094 had little effect on the cardiovascular responses to 5-hydroxytryptramine, angiotensin II, histamine, acetylcholine and isoprenaline in pithed rats and rats anaesthetized with pentobarbitone. 10 These results demonstrate that RX 781094 is a potent and selective alpha 2-adrenoceptor antagonist with a high degree of specificity for these receptors.

Full text

PDF
489

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cambridge D. UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1981 Jul 10;72(4):413–415. doi: 10.1016/0014-2999(81)90588-4. [DOI] [PubMed] [Google Scholar]
  3. Cavero I., Lefèvre-Borg F., Roach A. G. Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol. 1981 Sep;74(1):143–148. doi: 10.1111/j.1476-5381.1981.tb09966.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dabiré H., Mouillé P., Andréjak M., Fournier B., Schmitt H. Pre- and postsynaptic a-adrenoceptor blockade by (imidazolinyl-2)-2-benzodioxane 1-4 (170 150): antagonistic action on the central effects of clonidine. Arch Int Pharmacodyn Ther. 1981 Dec;254(2):252–270. [PubMed] [Google Scholar]
  5. Doxey J. C., Smith C. F., Walker J. M. Selectivity of blocking agents for pre-and postsynaptic alpha-adrenoceptors. Br J Pharmacol. 1977 May;60(1):91–96. doi: 10.1111/j.1476-5381.1977.tb16752.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. FOSTER R. W. The paired tracheal chain preparation. J Pharm Pharmacol. 1960 Mar;12:189–191. doi: 10.1111/j.2042-7158.1960.tb12652.x. [DOI] [PubMed] [Google Scholar]
  7. Langer S. Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1980 Dec;32(4):337–362. [PubMed] [Google Scholar]
  8. McGrath J. C. Evidence for more than one type of post-junctional alpha-adrenoceptor. Biochem Pharmacol. 1982 Feb 15;31(4):467–484. doi: 10.1016/0006-2952(82)90147-2. [DOI] [PubMed] [Google Scholar]
  9. Misu Y., Fujie K., Kubo T. Presynaptic dual inhibitory actions of guanabenz on adrenergic transmission. Eur J Pharmacol. 1982 Jan 22;77(2-3):177–181. doi: 10.1016/0014-2999(82)90016-4. [DOI] [PubMed] [Google Scholar]
  10. Natoff I. L., Dodge B. B. A method for the differentiation of presynaptic inhibitors of adrenergic neurotransmitter release. J Pharmacol Methods. 1980 Feb;3(2):159–165. doi: 10.1016/0160-5402(80)90025-x. [DOI] [PubMed] [Google Scholar]
  11. Roach A. G., Lefèvre F., Cavero I. Effects of prazosin and phentolamine on cardiac presynaptic alpha-adrenoceptors in the cat, dog and rat. Clin Exp Hypertens. 1978;1(1):87–101. doi: 10.3109/10641967809068597. [DOI] [PubMed] [Google Scholar]
  12. Scatton B., Zivkovic B., Dedek J. Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther. 1980 Nov;215(2):494–499. [PubMed] [Google Scholar]
  13. Starke K., Borowski E., Endo T. Preferential blockade of presynaptic alpha-adrenoceptors by yohimbine. Eur J Pharmacol. 1975 Dec;34(2):385–388. doi: 10.1016/0014-2999(75)90268-x. [DOI] [PubMed] [Google Scholar]
  14. VAN ROSSUM J. M. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther. 1963;143:299–330. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES